An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice

Therapeutic Strategies Including Avastin as 1st Line Therapy in Elderly Patients Suffering From Advanced (IIIB/IV Stage) Non-squamous Non-small Cell Lung Cancer, in Routine Clinical Practice.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01893268

Enrollment

279

Registered

2013-07-08

Start date

2013-07-25

Completion date

2018-03-20

Last updated

2018-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Brief summary

This prospective, observational study will assess the effectiveness and safety of Avastin (bevacizumab) as 1st line therapy in elderly patients with advanced non-squamous non-small cell lung cancer in clinical practice. Therapy with Avastin and standard chemotherapy will be administered according to the treating physician. Data will be collected for approximately 4 years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients, \>= 65 years of age * Diagnosis of advanced non squamous Non-Small Cell Lung Carcinoma (nsNSCLC, stage IIIB or IV) for whom the physician has decided to initiate a treatment with Avastin combined with chemotherapy as 1st line therapy * Having received oral and written information about the study, and having signed a written consent form

Exclusion criteria

* Participation in a cancer clinical trial with an investigational medicinal product other than this study * Patient previously treated with Avastin * Patient under supervision or guardianship

Design outcomes

Primary

Measure	Time frame
Proportion of patients treated with a chemotherapy in combination with Avastin including description of chemotherapy regimens and management of Avastin treatment	Approximately 4 years

Secondary

Measure	Time frame
Characteristics of patients with advanced non-squamous non-small cell lung cancer	Approximately 4 years
Tumor characteristics of patients with advanced non-squamous non-small cell lung cancer	Approximately 4 years
Progression-free survival	Approximately 4 years
Overall survival	Approximately 4 years
Quality of Life	Approximately 4 years
Safety: Incidence of adverse events	Approximately 4 years
Reasons of non-use of Avastin as first-line therapy	Approximately 4 years

Countries

France

Outcome results